Schedule-dependent PI3K/mTOR inhibition has a potential to reduce the frequency of side effects observed after PI3K/mTOR pathway inhibition by reducing number of administered doses required to achieve cytotoxic effects in cancer cells. Here, MTOR is linked to cancer.